menu search

IMRN / Immuron Limited (IMRN) Q4 2022 Earnings Call Transcript

Immuron Limited (IMRN) Q4 2022 Earnings Call Transcript
Immuron Limited (NASDAQ:IMRN ) Q4 2022 Earnings Conference Call September 6, 2022 7:00 PM ET Company Participants Steven Lydeamore - Chief Executive Officer Conference Call Participants Unidentified Company Representative Good morning, everyone. And welcome to Immuron's Full Year Results Webinar. Read More
Posted: Sep 6 2022, 23:53
Author Name: Seeking Alpha
Views: 102614

IMRN News  

Immuron CEO, Steven Lydeamore to present at H.C. Wainwright

By GlobeNewsWire
September 11, 2023

Immuron CEO, Steven Lydeamore to present at H.C. Wainwright

MELBOURNE, Australia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biophar more_horizontal

Immuron stock rockets after FDA removes hold on IND of infectious diarrhea treatment

By Market Watch
May 8, 2023

Immuron stock rockets after FDA removes hold on IND of infectious diarrhea treatment

The U.S.-listed shares of Immuron Ltd. IMRN powered up 66.3% toward a one-year high in premarket trading Monday, after the Australia-based biopharmace more_horizontal

Immuron CEO highlights strong sales growth in business update presentation

By Proactive Investors
March 6, 2023

Immuron CEO highlights strong sales growth in business update presentation

Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steven Lydeamore highlighted the strong growth in sales of oral immunotherapeutic products in the company's Fe more_horizontal

Immuron Limited (IMRN) Q4 2022 Earnings Call Transcript

By Seeking Alpha
September 6, 2022

Immuron Limited (IMRN) Q4 2022 Earnings Call Transcript

Immuron Limited (NASDAQ:IMRN ) Q4 2022 Earnings Conference Call September 6, 2022 7:00 PM ET Company Participants Steven Lydeamore - Chief Executive O more_horizontal

Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19

By Benzinga
October 8, 2021

Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19

Immuron Limited (NASDAQ: IMRN) has announced a recent publication of antiviral data from the IMM-124E preclinical and Phase 1/2a trials. The studie more_horizontal

Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19

By Benzinga
October 8, 2021

Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19

Immuron Limited (NASDAQ: IMRN) has announced a recent publication of antiviral data from the IMM-124E preclinical and Phase 1/2a trials. The studie more_horizontal

Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19

By Benzinga
October 8, 2021

Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19

Immuron Limited (NASDAQ: IMRN) has announced a recent publication of antiviral data from the IMM-124E preclinical and Phase 1/2a trials. The studie more_horizontal


Search within

Pages Search Results: